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Interaction between 
dopamine and 
endothelin receptor  
in hypertension
Many endothelin B or D3 dopamine 
receptor knockout mice develop 
hypertension. The question now arises 
of whether these findings constitute 
independent effects or events that occur 
in one pathway. To investigate the inter-
action between the endothelin B and 
D3 dopamine receptors, Zeng et al. 
infused mice with a D3 receptor agonist. 
In results published in this issue, they 
found that it caused natriuresis, which 
was partially blocked by an endothelin 
B receptor antagonist. Treatment with 
the D3 antagonist also caused endocyto-
sis of the D3 receptor into vesicles that 
contained the D3 receptor. However, 
combined treatment with both D3 and 
endothelin B antagonists failed to cause 
internalization of endothelin B receptors, 
which were located in the cell membrane. 
The authors also examined the interac-
tion of both receptors in spontaneously 
hypertensive rats; the D3 receptor antag-
onist blunted sodium excretion in this 
group. These studies demonstrate that 
the two receptors likely interact directly. 
Further, the blunted natriuretic response 
to dopamine in the spontaneously 
hypertensive rats might be produced by 
abnormal interactions between the two 
receptors. See page 750.
Bone growth after 
parathyroidectomy
Following parathyroidectomy, large 
increases in bone volume occur. The 
process responsible for this change could 
be due to remodeling or minimodeling. 
In minimodeling, the lamellar bone is 
formed in the absence of prior bone 
reabsorption. Now, Yajima et al. com-
pare the contributions of minimodeling 
and remodeling following parathyroid-
ectomy for secondary hyperparathy-
roidism. Using iliac bone biopsies, they 
found that osteoblast surface due to 
minimodeling was greater than the 
entire bone osteoblast surface before and 
at 10–12 weeks after parathyroidectomy, 
although no effect was found at earlier 
times after surgery. Minimodeling sig-
nificantly increased osteoid volume 3–4 
weeks after parathyroidectomy. They also 
found that osteoid formation in the first 
few weeks after surgery was more active 
at the minimodeling surface than at the 
entire bone surface. These studies show 
that bone formation by minimodeling is 
more active than by remodeling follow-
ing parathyroidectomy. See page 775.
Targeting 
hemoglobin and risk 
factors
Using erythropoietin to increase hemo-
globin in renal failure is nothing short of 
revolutionary; yet determining the appro-
priate target level has been vexing. Some 
trials have found that achieving higher 
hemoglobin levels resulted in worse out-
comes. In a study in this issue, Szczech 
et al. performed a 4-month, secondary 
analysis of the Correction of Hemoglobin 
and Outcomes in Renal Insufficiency 
(CHOIR) trial to estimate the competing 
benefit and harm from achieved hemo-
globin levels. In the high-hemoglobin-
target arm, more patients were unable to 
achieve their targeted hemoglobin levels, 
and thus required high-dose erythropoi-
etin, than were able to reach their targets. 
The inability to achieve a targeted level 
of hemoglobin and the requirement of 
a high dose of erythropoietin were sig-
nificantly associated with increased risk 
of death, myocardial infarction, conges-
tive heart failure, or stroke. However, the 
patients who reached their hemoglobin 
targets had better outcomes and no 
increased risk factors. Could it be that 
randomization of the trial was flawed? 
An examination of this hypothesis found 
it to be false. The result leaves us with 
the enigma of why some of the patients 
with high risk factors failed to reach their 
hemoglobin targets. See page 791.
